Meeting
2024 ASCO Breakthrough
Prevalence of pathogenic or likely pathogenic germline mutations in patients with metastatic renal cell cancer.
Authors
Atul Batra
Department of Medical Oncology, BRA-IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India
Atul Batra , Brusabhanu Nayak , Ranjit Kumar Sahoo , Seema Kaushal , Aparna Sharma , akash kumar , Amlesh Seth , Shamim Ahmed Shamim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 110)
DOI
10.1200/JCO.2024.42.23_suppl.110
Abstract #
110
Poster Bd #
G10
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Prevalence of pathogenic germline risk variants (PVs) in 1829 renal cell carcinoma (RCC) patients (pts).
First Author: Sarah Abou Alaiwi
Poster
2022 ASCO Genitourinary Cancers Symposium
Putative germline findings in tumor-only and liquid biopsy sequencing in veterans with aggressive prostate cancer.
First Author: Kara Noelle Maxwell
Poster
2017 ASCO Annual Meeting
Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.
First Author: Gregory Idos
Poster
2017 ASCO Annual Meeting
Expanded yield of multiplex panel testing in fully accrued prospective trial.
First Author: Gregory Idos